Workflow
What's Going On With MedTech Focused Inogen Stock On Wednesday?
InogenInogen(US:INGN) Benzingaยท2025-02-26 21:21

Core Insights - Inogen Inc reported a fourth-quarter adjusted EPS loss of 24 cents, an improvement from a loss of 83 cents a year ago, and better than the consensus loss of 61 cents [1] - The company achieved sales of $80.1 million, surpassing the consensus estimate of $73.9 million [1] Financial Performance - Total revenue in the fourth quarter of 2024 increased by 5.5% year over year, driven by higher demand and new customers in both international and domestic B2B sales, although this was partially offset by lower direct-to-consumer sales and rental revenue [2] - Adjusted EBITDA loss was $3.6 million in the fourth quarter of 2024, a significant improvement from a loss of $17.3 million a year ago [3] Future Guidance - Inogen expects first quarter 2025 sales to be between $79 million and $81 million, compared to the consensus of $78.1 million [4] - The company anticipates fiscal year 2025 sales of $352 million to $355 million, exceeding the consensus of $344.61 million [4] Analyst Reactions - JP Morgan views the initial guidance for Q1 2025 as a positive step towards normalized trends in the second half of 2025, despite unresolved supply challenges and uncertainties from a sales team restructuring [7] - Needham analyst maintains a Hold rating on Inogen, while William Blair notes strength in the B2B segments despite softer DTC and rental segments [7] - Analyst Margaret Kaczor Andrew believes the company is on a clear path to profitability, benefiting from recent management-driven changes [7]